News

Paris, France, September 15, 2022 – Tridek-One SAS, a biotech start-up and leader in the research and development of CD31 agonists to restore the immune balance, closed a € 16 million new round of financing led by Pureos Bioventures with participation of new investors bpifrance and Bioqube Ventures and historical investors

Tridek One, Paris, June 4, 2019 – Tridek-One, a biotech company specialized in the development of products for the treatment of immune disorders, is pleased to announce a first round of funding of € 3 million with leading investors Advent France Biotechnology and Advent Life Sciences.